Where I see patients (1)
My reviews
Selected research
- 
							The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.
							Clinical cancer research : an official journal of the American Association for Cancer Research
 - 
							Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.
							The oncologist
 - 
							Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.
							bioRxiv : the preprint server for biology
 
Clinical trials
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants W...
DFS is defined as the time from randomization to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, as assessed by the investigator, or death due to any cause, whichever occurs first.
Recruiting
					
				
														
														
														
														
														
				
					
				
4.9